Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

To join this study, you would typically need to have been diagnosed with advanced stomach, gastroesophageal junction, or gullet cancer that has previously been treated with one course of therapy. Your cancer shouldn't have specific HER2 markers, which doctors will check from a recent biopsy.

There are also general health requirements, such as your overall fitness level (doctors use a scale called ECOG, and you'd need to be a 0 or 1), and a life expectancy of at least 3 months. If you have conditions like Hepatitis B, Hepatitis C, or HIV, these would need to be well-managed and under control.

You wouldn't be able to join if your cancer is a specific type called squamous cell, or if you've had significant recent weight loss. Also, any side effects from your previous cancer treatments would need to have largely cleared up to a mild level.

If you join this study, you will receive one of the experimental drug combinations or the standard treatment. You'll have regular hospital visits for assessments, which will likely include blood tests, scans (like CT scans), and physical examinations to check how you're responding to the treatment and for any side effects. You'll take the study medication as prescribed by the doctors. The duration of the treatment phase will depend on how your cancer responds and how you tolerate the medication. Even after you stop receiving the study drug, there will be follow-up appointments to monitor your health.